The current price of GENB is $12.57 — it has decreased by 11.23% since the previous close. Data as of Nov 5, 2026.
GENB is down 15.41% over the past week, down 9.63% over the past month and down 0.63% over the past year. The price is below its 200-day moving average of $14.06.
Analysts' average 12-month price target for GENB is $26.00, which implies 106.84% upside from the current price. Individual estimates range from $22.00 to $30.00.
Of the 6 analysts covering Generate Biomedicines, Inc., 2 rate it a strong buy and 4 rate it a buy. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.
Generate Biomedicines, Inc. has a market capitalization of $1.61B. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.
In its most recent quarterly report, Generate Biomedicines, Inc. posted a loss of $0.52 per share against an estimate of -$0.5083, missing expectations by 2.30%. Upcoming reports are listed in the earnings calendar.
Generate Biomedicines, Inc. reported revenue of $6.31M in its most recent quarter. Analysts had expected $5.3M.
Generate Biomedicines, Inc. has not paid any dividends over the past year.
Companies most comparable to Generate Biomedicines, Inc. include AbCellera Biologics Inc., Absci Corporation, Inhibrx Biosciences Inc. and Sutro Biopharma, Inc.
In the latest trading session GENB moved between $12.46 and $14.11, a range of 13.13% of its current price.
Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of Generate Biomedicines, Inc. shows a strong sell rating today and a sell rating on the weekly timeframe. Technical ratings are indicators, not investment advice.
Over the past 52 weeks GENB has traded between $11.00 and $22.67. The current price is 44.55% below its 52-week high.
Figures as of Nov 5, 2026. This information is provided for general purposes only and is not investment advice.